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Neuronal lysosomal dysfunction releases
exosomes harboring APP C-terminal fragments and
unique lipid signatures
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Defects in endolysosomal and autophagic functions are increasingly viewed as key patho-
logical features of neurodegenerative disorders. A master regulator of these functions is
phosphatidylinositol-3-phosphate (PI3P), a phospholipid synthesized primarily by class III PI
3-kinase Vps34. Here we report that disruption of neuronal Vps34 function in vitro and
in vivo impairs autophagy, lysosomal degradation as well as lipid metabolism, causing
endolysosomal membrane damage. PI3P deﬁciency also promotes secretion of unique exo-
somes enriched for undigested lysosomal substrates, including amyloid precursor protein
C-terminal fragments (APP-CTFs), speciﬁc sphingolipids, and the phospholipid bis(mono-
acylglycero)phosphate (BMP), which normally resides in the internal vesicles of endolyso-
somes. Secretion of these exosomes requires neutral sphingomyelinase 2 and sphingolipid
synthesis. Our results reveal a homeostatic response counteracting lysosomal dysfunction via
secretion of atypical exosomes eliminating lysosomal waste and deﬁne exosomal APP-CTFs
and BMP as candidate biomarkers for endolysosomal dysfunction associated with neurode-
generative disorders.
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A variety of neurodegenerative disorders are associated withmajor defects in the endolysosomal pathway. Theseinclude Alzheimer’s disease1,2 (AD), Parkinson’s disease3
(PD), frontotemporal dementia (FTD)4, and several lysosome
storage disorders (LSD)1,5. The causal relationship between
endolysosomal dysfunction and neurodegeneration is demon-
strated by the occurrence of rare, LSD-causing familial mutations
that affect genes encoding key endolysosomal proteins, typically
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Fig. 1 Vps34 inhibition induces early endosomal abnormalities and causes accumulation of APP-CTFs. a, b Representative confocal images of cultured
cortical neurons treated with vehicle or VPS34IN1 at 3 µM for 3 h. a Super-resolution Airyscan insets and arrows highlight EEA1 endosomes. Bar graphs
indicate average EEA1-puncta size, per cell (mean± SEM, N= 37 and 44 cells, respectively, from three independent experiments) and average EEA1/Rab5
puncta intensity, per cell (mean± SEM, N= 55 and 63 for vehicle and VPS34IN1, respectively). b Airyscan insets highlight colocalization between APPL1
and Rab5. Bar graph indicates fraction of APPL1 signal colocalizing with Rab5 (mean± SEM, N= 35 cells, from three independent experiments). Scale bar,
10 µm. ***p< 0.001 in two-tailed Student’s t test. c Western blot analysis of Cathepsin D levels in primary cortical neurons treated with vehicle or
VPS34IN1 at 3 µM for 24 h. Bar graph represents average protein levels of total CatD (sum of CatD and proCatD) or ratio of CatD/proCatD, normalized to
vehicle (mean± SEM, N= 7, from two independent experiments). Right panel, representative confocal images of primary cortical neurons. Airyscan insets
highlight luminal sorting of Cathepsin D in LAMP-1-positive compartments. Scale bar, 10 µm. ***p< 0.001 in two-tailed Student’s t test. d, e Western blot
analysis of APP metabolites from primary cortical neurons treated as in c or N2a cells treated with VPS34IN1 at 1 µM for 24 h. Bar graph denotes average
protein levels normalized to vehicle (mean± SEM, N= 6 and 7, respectively, for primary neurons; N= 8 and 7, respectively, for N2a cells, from two
independent experiments) and murine Aβ40 and Aβ42 levels measured by MSD from culture media (mean± SEM, N= 12 and 13, respectively, for primary
neurons; N= 8 and 7, respectively, for N2a cells, from two independent experiments). Aβ levels were normalized to lysate total protein. *p< 0.05, **p<
0.01, ***p< 0.001 in two-tailed Student’s t test
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resulting in aggressive, childhood-onset LSDs associated with
neurodegeneration (e.g., Niemann–Pick disease type C or NPC)5,6.
More recently, mutations in a variety of genes involved in
endocytic or endolysosomal function have been shown to cause
PD (e.g., LRRK2) or some forms of parkinsonism (e.g., VPS35,
SYNJ1, ATP13A2)3. Importantly, homozygous mutations in cer-
tain genes cause LSDs (e.g., GBA and GRN), while heterozygous
mutations of the same genes are major genetic risk factors for
late-onset neurodegenerative diseases, such as PD and FTD,
respectively3,4. Finally, several genes involved in the regulation of
endolysosomal function have also been linked to late-onset AD
(LOAD) suggesting this process to be a key driver of disease onset
and progression7.
Lysosomes are central organelles for the degradation of a large
number of macromolecules targeted to this compartment via the
endocytic and autophagic pathways1,5,6. Failure to properly
degrade these substrates leads to their accumulation, within the
endolysosomal compartment itself (e.g., glycosphingolipids), in
the cytoplasm (e.g., tau, α-synuclein, ubiquitin inclusions) or in
the extracellular environment (e.g., amyloid plaques)1,5,6. A key
molecular pathway controlling endolysosomal function and
autophagy is the class III phosphatidylinositol-3-kinase (PI3K-
III)/Vps34 signaling pathway, which leads to the phosphorylation
of PI on the 3’ position of the inositol ring, generating PI3P.
Vps34 interacts with p150/Vps15 and Beclin 1, forming either
complex I with ATG14L or complex II with UVRAG. Although
complex I synthesizes PI3P on pre-autophagosomal membranes,
complex II produces PI3P on early endosomes8,9. PI3P, in turn,
controls the membrane recruitment of a variety of cytosolic
effectors harboring PI3P-binding domains, including FYVE and
PX modules9,10. PI3P also serves as a substrate for the synthesis of
PI(3,5)P2 by the PI3P 5-kinase PIKfyve on late endosomes,
controlling additional aspects of endolysosomal function10,11.
Altogether, this pathway mediates a variety of critical processes,
such as endosomal fusion, intraluminal vesicle (ILV) budding,
endosomal motility as well as the biogenesis and maturation of
autophagosomes during macroautophagy (simply referred as
autophagy)9,10.
In neurons, conditional knockout of Vps34 causes progressive
synaptic loss followed by extensive gliosis and neurodegenera-
tion12,13. While no human mutations in PIK3C3, the gene
encoding Vps34, have been associated with neurodegenerative
disorders, the relevance of the PI3P/PI(3,5)P2 pathway in neu-
rological disorders is supported by the existence of amyotrophic
lateral sclerosis (ALS) and Charcot–Marie–Tooth 4 J (CMT4J)
causing mutations in FIG4 as well as PD causing mutations in
VAC14, both of which are key components of the PIKfyve
complex controlling PI(3,5)P2 metabolism11,14. In addition, we
have recently reported that PI3P is selectively deﬁcient in the
brain of patients with AD and mouse models thereof15. Fur-
thermore, silencing Vps34 in primary neurons was shown to
cause endosomal anomalies and altered amyloidogenic processing
of amyloid precursor protein (APP), which are important
pathological features of AD1,2. Overall, these studies implicate
dysregulation of the PI3P pathway and associated endolysosomal
perturbation in neurodegeneration.
In this study, we employ pharmacological inhibition and
genetic ablation of Vps34 in mice to assess the impact of PI3P
deﬁciency on neuronal autophagy and endolysosomal function,
with emphasis on APP and lipid metabolism. We conﬁrm that
disruption of Vps34 function impairs endolysosomal function
and report a profound alteration of cellular lipid metabolism
consistent with a LSD. PI3P depletion promoted the physical
disruption of endolysosomal membranes and secretion of exo-
somes harboring APP C-terminal fragments (APP-CTFs) and
unique lipid signatures, including an enrichment of the
endolysosomal phospholipid bis(monoacylglycero)phosphate
(BMP) (also known as lysobisphosphatidic acid or LBPA)16. We
show that release of these atypical exosomes is blocked by inhi-
bition of neutral sphingomyelinase 2 (nSMase2) and de novo
sphingolipid synthesis. Together, our results demonstrate that
endolysosomal dysfunction triggers a homeostatic response
leading to the secretion of atypical exosomes, allowing for elim-
ination of lysosomal contents that cannot be efﬁciently degraded.
They further highlight the potential of exosomes as biomarkers
for neurodegenerative disorders involving endolysosomal
dysfunction.
Results
PI3P depletion causes endosomal dysfunction. To test the role
of PI3P in endosomal function, we used the newly developed highly
speciﬁc Vps34 kinase inhibitor VPS34IN117 (see also refs. 18,19),
which selectively decreased PI3P by ~50% after 24 h in the
murine neuroblastoma line N2a (Supplementary Fig. 1a). Drug
treatment increased Beclin 1 levels, but did not downregulate its
other interacting partners from complex I, namely ATG14L and
Vps15, in contrast to knockout of Vps3420, ruling out indirect
effects of destabilization of these proteins (Supplementary
Fig. 1b). Importantly, a 24 h treatment with VPS34IN1 did not
affect neuronal cell viability in vitro (Supplementary Fig. 1c).
Next, we investigated the impact of Vps34 inhibition on early
endosomal trafﬁcking in primary mouse cortical neurons.
Pharmacological inhibition of Vps34 for 3 h caused a ~50%
increase in the diameter of EEA1-positive endosomal puncta
(Fig. 1a), in agreement with previous Vps34 silencing experi-
ments in neurons15. EEA1 ﬂuorescence intensity was decreased
by ~30% after Vps34 inhibition (Fig. 1a), likely reﬂecting reduced
membrane association of this PI3P-interacting protein9,10. This
was conﬁrmed in N2a cells fractionated in particulate and soluble
fractions, showing higher levels of soluble EEA1, but not Rab5, in
VPS34IN1-treated cells (Supplementary Fig. 1d). Rab5 puncta
intensity and size were also signiﬁcantly increased (Fig. 1a and
Supplementary Fig. 1e). Upon Vps34 inhibition, Rab5 showed
increased colocalization with APPL1 (Fig. 1b), a protein that
associates with PI3P-negative early endosomes21. These observa-
tions conﬁrm the key role of Vps34 kinase activity in early
endosomal trafﬁc in neurons.
Vps34 inhibition slows lysosomal degradation of APP-CTFs.
Vps34 controls endolysosomal function in non-neuronal cells, in
part by mediating sorting via the ESCRT pathway and delivery of
hydrolases to lysosomes10. Here we found that neurons treated
with VPS34IN1 for 4 h show delayed degradation of the EGF
receptor following EGF stimulation (Supplementary Fig. 2a). The
remaining degradation was blocked by V-ATPase inhibitor baﬁ-
lomycin A1 (BafA1), suggesting that Vps34 inhibition only par-
tially impairs lysosomal function (Supplementary Fig. 2b). Next,
we assessed the maturation of Cathepsin D (CatD), a lysosomal
hydrolase produced in the biosynthetic pathway as precursor
proCatD (~50 kDa) and sorted to the endolysosomal compart-
ment, where it is processed into a mature form (~30 kD) at acidic
pH22. Vps34 inhibition for 24 h caused a defect in CatD
maturation, based on the decreased CatD/proCatD ratio, but not
in total levels (Fig. 1c). However, confocal analysis of CatD
showed that its sorting into the endolysosomal lumen was not
grossly affected (Fig. 1c).
We next investigated the impact of acute PI3P depletion on the
processing of endogenous APP. The C-terminal fragments of
APP α (APP-CTFα) and β (APP-CTFβ), which are produced by
α-secretase and β-secretase, respectively, and further processed by
γ-secretase, are known to accumulate as a result of lysosomal
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Fig. 2 Vps34 inhibition blocks autophagy initiation and causes accumulation of ubiquitin-positive and p62-positive structures. a Representative confocal
images of cortical neurons treated with vehicle, Baﬁlomycin A1 (BafA1) at 50 nM, VPS34IN1 at 3 µM or cotreated for 3 h. Arrows highlight LC3 and
p62 structures. Right panel, bar graphs denote average object intensity, per cell (mean± SEM, N= 49-60 cells, from three independent experiments).
Scale bar, 10 µm. ***p< 0.001 in one-way ANOVA, Holm–Sidak’s multiple comparisons test. b Representative confocal images of cortical neurons treated
as in a and immunostained for LAMP-1, LC3, and p62. Airyscan insets highlight position of LC3 and p62 structures relative to LAMP-1-positive membranes.
Scale bar, 10 µm. c Representative confocal images of cultured cortical neurons treated with vehicle or VPS34IN1 at 3 µM for 24 h. Arrows highlight p62
and ubiquitin colocalization. Scale bar, 10 µm
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dysfunction23. Vps34 inhibition caused a ~40% increase in APP-
CTFα/β (hereafter referred to as APP-CTFs) levels without
altering levels of full-length APP (FL-APP; Fig. 1d). Of note, the
BACE-1 cleavage product, APP-CTFβ, was also increased by
~40%. Contrary to effects observed upon Vps34 silencing15, levels
of secreted γ-secretase products Aβ40 and Aβ42 were decreased
by ~20–25% after Vps34 inhibition (Fig. 1d). Blocking Vps34 in
N2a cells caused a more robust increase in total APP-CTF levels
and APP-CTFβ speciﬁcally, while Aβ40 and Aβ42 secretion was
decreased by 40–65% (Fig. 1e).
To test if APP-CTF accumulation results from decreased
lysosomal degradation rather than decreased γ-secretase
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processing, we pulse-treated N2a cells with protein synthesis
inhibitor cycloheximide and monitored FL-APP and APP-CTF
levels for 6 h (Supplementary Fig. 2c). While VPS34IN1 did not
affect FL-APP turnover, it caused a delay in APP-CTF
degradation, particularly at 2 h (Supplementary Fig. 2c). To
exclude processing defects by γ-secretase, cells were also co-
incubated with the γ-secretase inhibitor, compound XXI (XXI γ-
inhibitor) (Supplementary Fig. 2d). XXI γ-inhibitor extended
APP-CTF half-life relative to cycloheximide alone (i.e., from 2 to
4 h), conﬁrming that γ-secretase cleavage is a main pathway for
the clearance of APP-CTFs. However, Vps34 inhibition still
signiﬁcantly delayed APP-CTF clearance despite γ-secretase
inhibition (Supplementary Fig. 2d), conﬁrming that a signiﬁcant
amount of APP-CTFs are degraded in lysosomes in a Vps34-
dependent fashion.
Vps34 inhibition blocks autophagy initiation. Next, we assessed
the autophagic ﬂux by treating neurons for 3 h with BafA1 to
block the clearance of autophagosomes in the presence or absence
of VPS34IN1. While BafA1 alone caused a ~2-fold increase in the
ﬂuorescence of LC3-positive structures (Fig. 2a) and a ~5-fold
increase in lipidated LC3 (LC3-II) by immunoblotting (Supple-
mentary Fig. 3a), these effects were blocked by Vps34 inhibition,
indicating inhibition of autophagosome formation. Next, we
investigated the autophagy adapter p62, which delivers poly-
ubiquitinated cargoes to growing autophagosomes via its
ubiquitin-associated domain and LC3-interacting region. As an
autophagy substrate, p62 accumulates and aggregates in
ubiquitin-positive structures when autophagy is impaired24.
Vps34 inhibition caused a ~2-fold increase in the ﬂuorescence of
p62-positive structures (Fig. 2a), similar to BafA1 alone or after
combined treatments (Supplementary Fig. 3a). Remarkably,
super-resolution Airyscan confocal images showed that p62-
positive puncta do not accumulate in the lumen of LAMP-1-
positive late endosomes/lysosomes upon Vps34 inhibition, while
they were observed in those of BafA1-treated cells (Fig. 2b). This
suggests that sorting of p62 structures into late endosomes/lyso-
somes requires PI3P-dependent autophagosome formation, a
process that is not altered by BafA1. Electron microscopic (EM)
analysis of VPS34IN1-treated cortical neurons revealed enlarged
vacuoles with decreased intraluminal material and previously
observed electron dense structures25 in the vicinity of endocytic
compartments (Supplementary Fig. 3b), which morphologically
resemble LAMP-1 and p62-positive structures detected by
immunoﬂuorescence (Fig. 2b). Additionally, ubiquitin-positive
inclusions co-localizing with p62 were revealed by confocal
microscopy after a 24 h treatment with VPS34IN1 (Fig. 2c),
consistent with the accumulation of poly-ubiquitinated proteins
and p62 observed by immunoblotting (Supplementary Fig. 3c).
These results were conﬁrmed in primary cortical neurons lacking
Vps34 as a result of lentiviral expression of Cre recombinase in a
Pik3c3ﬂox/ﬂox background (Supplementary Fig. 3d, e) and there-
fore highlight the essential role of Vps34 and its kinase activity in
neuronal autophagy.
Lipid metabolism is severely affected by Vps34 inhibition.
Given the deleterious impact of Vps34 inhibition on endolyso-
somal/autophagic function, we hypothesized that a broader, sec-
ondary lipid dysregulation may result from PI3P deﬁciency. We
used liquid chromatography–mass spectrometry (LC–MS) to
analyze the lipid composition of cultured cortical neurons fol-
lowing Vps34 inhibition. Of all lipid classes, sphingolipids were
the most signiﬁcantly impaired, particularly ceramide (Cer),
dihydroceramide (dhCer) and dihydrosphingomyelin (dhSM)
(Fig. 3a), for which many molecular species were increased
(Supplementary Fig. 4a). Additionally, levels of BMP were
quantiﬁed. BMP is predominantly enriched in ILVs of late
endosomes16 and is known to be elevated in LSDs, such as NPC26
as well as in the brain of AD patients27. Although no changes in
total BMP levels were found after VPS34IN1 treatment, several
molecular species of this phospholipid were increased (Fig. 3a;
Supplementary Fig. 4b). While only diffuse immunostaining of
BMP was detected in primary neurons, immunostaining of N2a
cells conﬁrmed the luminal localization of this phospholipid in
LAMP-1 compartments in both control and treated conditions,
suggesting that no gross alteration of BMP localization occurs in
these organelles upon Vps34 inhibition, which also caused a clear
accumulation of p62 in their vicinity (Supplementary Fig. 4c).
Overall, these data indicate that reducing PI3P synthesis causes a
secondary perturbation of lipid metabolism.
Vps34 inhibition causes endolysosomal membrane damage.
Next, we tested if endolysosomal compartments are physically
disrupted by Vps34 inhibition. We thus stained VPS34IN1-
treated primary cortical neurons for galectin-3, a recently estab-
lished marker for endolysosomal membrane damage28, and
observed an increase in the number of galectin-3-positive struc-
tures (Fig. 3b, c). Galectin-3 puncta greatly colocalized with p62,
as well as ubiquitin, and were generally juxtaposed to and distinct
from LAMP-1 compartments. In fact, super-resolution confocal
and linescan analyses evidenced the segregation of p62/galectin-3
intensity peaks from LAMP-1 membranes and luminal exclusion
of these structures (Fig. 3b, c). We also found colocalization
between galectin-3, p62, and ﬂotillin-2, a membrane-associated
protein commonly used to identify cholesterol-enriched and
sphingolipid-enriched microdomains29 (Fig. 3d). Although APP-
CTFs accumulate in VPS34IN1-treated neurons, immunostain-
ings of APP and APP-CTFs did not colocalize with p62 (Sup-
plementary Fig. 4d), suggesting that APP does not accumulate on
damaged endolysosomal structures. Together with the ﬁnding
that genetic ablation of Vps34 in cultured neurons also increases
the number of galectin-3 puncta and their colocalization with p62
(Supplementary Fig. 5), our data suggest that Vps34 inhibition
results in physical damage of endolysosomal membranes. Proxi-
mity to but lack of luminal sorting into LAMP-1 compartments
indicates these damaged organelles are marked for degradation
via ubiquitination and recruitment of autophagy adapter p62, but
they are not efﬁciently eliminated by selective autophagy28, likely
from the reduced ability to lipidate LC3 upon Vps34 inhibition.
Fig. 3 Vps34 inhibition causes cellular accumulation of sphingolipids and induces endolysosomal membrane damage. a LC–MS analysis of lipids extracted
from primary cortical neurons treated with vehicle or VPS34IN1 at 3 µM for 24 h. For lipid nomenclature, see Methods section. Values are expressed as
average Mol% of total lipid measured, normalized to vehicle (mean± SEM, N= 8, from two independent experiments). *p< 0.05, **p< 0.01 in two-tailed
Student’s t test. b–d Representative confocal images of cultured cortical neurons treated as in a. b Airyscan insets highlight triple colocalization between
galectin-3, ubiquitin, and p62. Bar graphs indicate average number of galectin-3 puncta per cell (mean± SEM, N= 40 cells, from three independent
experiments), fraction of galectin-3 colocalizing with p62, and ubiquitin colocalizing with galectin-3 (mean± SEM, N= 30 cells, from three independent
experiments). c Airyscan insets highlight p62 and galectin-3 colocalization in close proximity to LAMP-1-positive membranes. Right panel, linescan
intensity proﬁle for adjacent p62/galectin-3 and LAMP-1 structures. d Airyscan insets and linescan intensity proﬁle highlight triple colocalization between
galectin-3, p62, and ﬂotillin-2. Scale bar, 10 µm
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Fig. 4 VPS34IN1 treatment causes secretion of extracellular vesicles (EVs) enriched for APP-CTFs, sphingolipids and BMP. a, b Western blot analysis of
cell lysates and EVs from primary cortical neurons treated with vehicle or VPS34IN1 at 3 µM for 24 h. EV protein levels were normalized to lysate total
protein (EV total) or lysate levels of the corresponding protein (EV/Lysate ratio). Bar graph denotes average protein levels normalized to vehicle (mean±
SEM, N= 4 for cell lysates, N= 6 for EVs, from two independent experiments). **p< 0.01, ***p< 0.001 in two-tailed Student’s t test. c LC–MS analysis of
lipids extracted from EVs collected from primary cortical neuron culture media after treatment as in a. Values are expressed as average Mol% of total lipid
measured, normalized to vehicle (mean± SEM, N= 3, each from a pool of two biological replicates). *p< 0.05, **p< 0.01, ***p< 0.01 in two-tailed
Student’s t test. d, e Western blot and LC–MS analysis of lipids extracted from EVs collected from N2a cell culture media after treatment with vehicle or
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Whether these damaged organelles are early endosome or late
endosomes/lysosomes that have lost their membrane markers
through proteolysis as a result of membrane damage remains
unclear.
APP-CTFs are secreted in BMP-enriched exosomes. Lysosomal
stress has been hypothesized to cause the release of extracellular
vesicles (EVs), such as exosomes, as an alternative pathway
mediating the elimination of cellular waste, including toxic pro-
tein aggregates and lipids30–32. Exosomes are small 40–100 nm
vesicles that are released when multivesicular endosomes fuse
with the plasma membrane33.
The association of ﬂotillin-2 with damaged endolysosomal
membranes and the fact that ﬂotillins have been reported on
EVs33 prompted us to determine if VPS34IN1-induced endoly-
sosomal dysfunction promotes EV release. EVs were puriﬁed by
ﬁltration and ultracentrifugation of cell media34,35 (Supplemen-
tary Fig. 6a, b). In primary cortical neurons, Vps34 inhibition
increased secretion of three EV markers (ALIX, Flotillin-1, and
Flotillin-2) by ~3-fold, while levels of the same markers were
unaffected in cell lysates (Fig. 4a, b). Given the effect of Vps34
blockade on APP metabolism, we examined levels of FL-APP and
APP-CTFs in EVs (Fig. 4b). Remarkably, APP-CTFs were
increased to a greater extent than FL-APP (6-fold vs. 3-fold,
respectively), suggesting that APP-CTFs are sorted more
efﬁciently to EVs. However, since APP-CTFs levels were also
higher in lysates from VPS34IN1-treated cells (Fig. 1d), the fold
increase in EV secretion was comparable for FL-APP and APP-
CTFs when normalized to lysate levels of the same proteins
(Fig. 4b). Since poly-ubiquitinated proteins as well as p62 have
been previously reported on EVs36,37, we blotted the EV fractions
with anti-ubiquitin and anti-p62 antibodies and found increased
levels upon VPS34IN1 treatment, supporting the hypothesis that
EVs can be used as a vehicle for the disposal of undigested
material (Fig. 4b).
We next analyzed EV lipid composition by LC–MS. EVs from
VPS34IN1-treated cortical neurons were enriched for cholesterol
and speciﬁc sphingolipid subclasses, namely dhSM, monohex-
osylceramide (MhCer) and lactosylceramide (LacCer) (Fig. 4c)
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relative to controls. The most robust change, however, was a
∼2.5-fold increase in total BMP (Fig. 4c), reﬂecting increase in
multiple molecular species of this phospholipid (Supplementary
Fig. 6c). These results were validated in N2a cells, as EV-
associated APP-CTFs, FL-APP, ﬂotillin-1, and -2 levels were all
increased (Fig. 4d, e). Of note, proteins typically associated with
the number of exosomes, ALIX and CD63, or ESCRT-dependent
ILV sorting, Tsg101 and Hrs, were minimally affected, suggesting
that Vps34 inhibition likely affects composition rather than
quantity of EVs in an ESCRT-independent fashion (Fig. 4d and
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data not shown). Lipidomic proﬁling showed an increase in an
overlapping set of sphingolipid subclasses, such as MhCer and
LacCer, and a striking ∼20-fold increase in BMP levels, including
all individual molecular species detected (Fig. 4e, Supplementary
Fig. 6d). Additionally, while a ~70% increase in dhSM levels was
also detected (p = 0.05), Cer levels were increased by ~50% in
contrast to the ~10% decrease found in primary neuron-derived
EVs (Fig. 4c). These results were also conﬁrmed using a
chemically-distinct Vps34 kinase inhibitor, SAR40519, indicating
on-target effects (data not shown). Altogether, our observations
suggest that EVs secreted upon PI3P depletion result from
endolysosomal/autophagic dysfunction and are exosomes, based
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on the fact that BMP is associated with ILVs16 and is thus a bona
ﬁde marker for these organelles16.
APP-CTF secretion requires endolysosomal dysfunction. To
investigate if APP-CTF exosomal secretion merely reﬂects intra-
cellular accumulation, we compared the effect of Vps34 inhibition
to γ-secretase inhibition, which dramatically increases cellular
APP-CTF levels, but does not cause major alterations of the
endolysosomal system38. N2a cells were treated for 24 h with the
XXI γ-inhibitor and VPS34IN1, either singly or in combination.
Cellular APP-CTF levels were increased by XXI γ-inhibitor to a
higher extent than VPS34IN1 alone, while they were additively
increased by combined treatment (Supplementary Fig. 7a).
Consistent with a lack of impact on autophagic/lysosomal func-
tion, the XXI γ-inhibitor alone did not affect total p62 levels
(Supplementary Fig. 7a). Remarkably, despite the robust accu-
mulation of APP-CTFs observed after XXI γ-inhibitor39, a
smaller proportion was released on EVs relative to vehicle or
VPS34IN1 treatment (Supplementary Fig. 7b, low and high
exposure panels). Combined treatments caused an additive
increase in EV-associated APP-CTFs relative to VPS34 inhibition
alone, but to a lesser extent than that observed in lysates (Sup-
plementary Fig. 7b). These data suggest that active sorting of
APP-CTFs into EVs occurs as a result of Vps34 inhibition and
that the amount of EV-associated APP-CTF does not simply
reﬂect cellular APP-CTF levels.
Next, we sought to precisely delineate the role of autophagy
blockade vs. endolysosomal dysfunction by VPS34IN1 on
exosomal secretion of APP-CTFs. To speciﬁcally assess the
contribution of autophagy, we used CRISPR-Cas9 gene-edited
N2a cells lacking Atg5 (Atg5 KO), a core component of the
autophagy machinery40. Atg5 ablation was conﬁrmed by the
absence of Atg12-Atg5 conjugates (Supplementary Fig. 7c). Atg5
KO N2a cell lysates showed increased basal cellular levels of p62
and APP-CTFs relatively to isogenic controls. Interestingly,
Vps34 inhibition caused a similar fold increase in cellular p62
and APP-CTF levels in both cell lines, in addition to baseline
effects induced by Atg5 KO (Supplementary Fig. 7c). While Atg5
KO alone showed a trend for increased secretion of the EV
markers analyzed, VPS34IN1 treatment caused a much more
dramatic effect in EV-associated APP-CTFs and a comparable
fold increase in both naive and Atg5 KO cells (Supplementary
Fig. 7d). Therefore, we conclude that the increase of APP-CTF
secretion via EVs induced by Vps34 inhibition occurs indepen-
dently of major autophagy defects and suggests it originates from
other aspects of endolysosomal dysfunction.
We also investigated whether exosomal APP-CTF levels are
affected by endolysosomal alkalization induced by treating N2a
cells with BafA1 for 24 h. Western blot analysis of cell lysates
showed that BafA1 treatment causes a dramatic increase in p62
levels as well as in APP-CTFs (Fig. 5a). In contrast, cellular
ﬂotillin-2 levels were decreased by ~50% upon BafA1 treatment.
BafA1-treated cells showed a striking increase in ﬂotillin-2, p62
and APP-CTFs in EVs, although the latter was proportional to
cellular levels (Fig. 5b). In addition, LC–MS analysis of EVs from
BafA1-treated cells showed a ~20% enrichment for cholesterol
and a ~2-fold increase in the sphingolipid subclasses Cer, dhCer,
MhCer, and LacCer (Fig. 5c). BMP levels were increased by ~2-
fold as seen in N2a cells and primary neurons treated with
VPS34IN1 (Fig. 5c). Altogether, these results suggest that release
of EVs enriched for APP-CTFs and lipids of late endocytic/
lysosomal compartments is intrinsically related to endolysosomal
dysfunction.
Exosome secretion is modulated by ceramide synthesis. Cer
production by nSMase2 has been directly implicated in exosome
biogenesis and secretion41,42. Considering the impact of Vps34
inhibition on Cer metabolism, we tested if GW4869, a nSMase2
inhibitor, affects exosomal secretion of APP-CTFs induced by
VPS34IN1. Cotreatment of primary cortical neurons with
VPS34IN1 and GW4869 increased the cellular accumulation of
APP-CTFs relative to VPS34IN1 alone (Fig. 6a). In contrast, no
changes were observed for cellular ﬂotillin-2 levels (Fig. 6a).
GW4869 caused an overall decrease in EV secretion, based on the
reduction of ALIX, ﬂotillin-2, APP-CTFs and poly-ubiquitinated
protein levels observed in EV fractions (Fig. 6b). The effect of
nSMase2 inhibition on exosomes was largely phenocopied by
treatment with myriocin, which inhibits serine palmitoyl trans-
ferase, i.e., the enzyme catalyzing the ﬁrst step in de novo
sphingolipid synthesis (Fig. 6c, d). These results suggest that
exosome secretion quantitatively alleviates intracellular burden
and implicate sphingolipid metabolism in the sorting and secre-
tion of APP-CTFs in exosomes.
Vps34 ablation in neurons alters brain exosome composition.
To validate the role of neuronal Vps34 in endolysosomal function
and exosome secretion in vivo, we conditionally deleted the gene
encoding Vps34 in forebrain excitatory pyramidal neurons by
crossing CaMKII-Cre transgenic mice with Pik3c3ﬂox/ﬂox mice
(Pik3c3 cKO). Mutant mice show extensive gliosis and pro-
gressive neuronal loss in the hippocampus and cortex, as
described previously12. Here, mouse hippocampi were analyzed at
2 months of age, approximately a month after Cre expression in
the forebrain and prior to neurodegeneration, as shown with
comparable MAP2 stainings in neurons from both genotypes, in
contrast with 3-month-old mice which show a profound decrease
in MAP2 stainings in Pik3c3 cKO brain (Fig. 7a and Supple-
mentary Fig. 8a)12. Total Vps34 and Beclin 1 protein levels were
decreased by ~30% in Pik3c3 cKO mice, with the remaining
expression likely resulting from glial cells as well as inhibitory
neurons (Fig. 7b). As expected, Pik3c3 cKO mice showed accu-
mulation of poly-ubiquitinated proteins and p62, indicating
endolysosomal/autophagic defects (Fig. 7b). As seen in vitro,
Vps34 deﬁciency increased levels of APP-CTFs (including APP-
CTFβ) but not FL-APP (Fig. 7c). However, hippocampal Aβ40
and Aβ42 levels were unchanged (Fig. 7c).
Fig. 7 Neuronal Vps34 deﬁciency in vivo leads to endolysosomal dysfunction and increased exosomal APP-CTF sorting. a Brain sections from 2-month-old
Pik3c3ﬂox/ﬂox (CTRL) and Pik3c3ﬂox/ﬂox; CaMKII-Cre (Pik3c3 cKO) mice immunostained for MAP2 and p62. Scale bar, 500 µm. b, cWestern blot analysis of
hippocampus lysates from 2-month-old CTRL and Pik3c3 cKO mice (mean± SEM, N= 7 and 8, respectively in b; N= 8 in c, from two independent
experiments). c Right panel, soluble Aβ40 and Aβ42 levels in hippocampus lysates of 2-month-old CTRL and Pik3c3 cKO mice (mean± SEM, N= 9 mice,
from two independent experiments). *p< 0.05, **p< 0.01, ***p< 0.001 in two-tailed Student’s t test. d LC–MS analysis of lipids extracted from
hippocampus lysates of 2-month-old CTRL and Pik3c3 cKO mice. Values are expressed as average Mol% of total lipids measured, normalized to CTRL.
(mean± SEM, N= 8 and 9, respectively, from two independent experiments). *p< 0.05, ***p< 0.001 in two-tailed Student’s t test. eWestern blot analysis
of EVs isolated from the forebrain of 2-month-old CTRL and Pik3c3 cKO mice. Bar graph denotes average protein levels normalized to CTRL (mean± SEM,
N= 4 mice, from two independent experiments). *p< 0.05 in two-tailed Student’s t test. f LC–MS analysis of EVs from 2-month-old CTRL and Pik3c3 cKO
mice. Values are express ed as average Mol% of total lipids measured, normalized to CTRL. For complete lipid panel and BMP species analysis, see
Supplementary Fig. 8e. (mean± SEM, N= 6 mice, from two independent experiments). *p< 0.05, **p< 0.01 in two-tailed Student’s t test
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Next, we characterized the hippocampal lipidome. As observed
in vitro, sphingolipid metabolism was affected with increased Cer
and dhCer in Pik3c3 cKO relative to control mice (CTRL)
(Fig. 7d). BMP levels were also increased, consistent with
endolysosomal impairment. We also found an increase in
monoacylglycerol (MG) and, more striking, in cholesterol esters
(CE), perhaps reﬂecting reactive gliosis and phagocytic activity43.
To investigate the secretion of APP-CTFs via EVs, brain
exosomes were puriﬁed by step gradient fractionation42,44
(Supplementary Fig. 8b, c, d). Analysis of exosomal markers
revealed a ~2.5-fold increase in ALIX but no changes in ﬂotillin-1
or ﬂotillin-2 in exosomes from Pik3c3 cKO brain, relative to
controls (Fig. 7e). Importantly, we observed a ~2-fold increase in
exosomal poly-ubiquitinated proteins and APP-CTFs in Pik3c3
cKO brain (Fig. 7e). FL-APP and p62 were not detected in
puriﬁed exosomes, in contrast to those puriﬁed in vitro.
Furthermore, lipidomic analysis of brain EVs revealed an increase
in total SM, LacCer and BMP, with an increase in most BMP
species detected (Fig. 7f and Supplementary Fig. 8e). While
changes were generally more subtle than those observed in vitro,
a more global alteration of phospholipids was found in
hippocampal exosomes as well as increases in CE and MG, as
seen in hippocampal tissue (Fig. 7d). Altogether, these results
conﬁrm that ablation of Vps34 in neurons in vivo induces
endolysosomal dysfunction and lipid dysregulation, which are
associated with the release of exosomes enriched for APP-CTFs
and various lipids, including BMP.
Discussion
Based on our previous work showing a deﬁciency of PI3P in AD
brain15, we have investigated the impact of neuronal Vps34
kinase inhibition and genetic ablation on endolysosomal function,
autophagy, and APP metabolism. We found that blocking Vps34
leads to a profound dysregulation of lipid metabolism and
endolysosomal membrane disruption, accumulation, and secre-
tion of APP-CTFs on a subpopulation of exosomes also enriched
for ubiquitinated proteins and atypical lipids such as BMP,
demonstrating that neurons have the capacity to eliminate
undigested, potentially toxic endolysosomal cargoes via exosomes.
Dysregulation of the endocytic pathway in neurons is
increasingly viewed as one of the earliest pathological events in
the pre-clinical stage of LOAD, even preceding autophagy dis-
turbances also reported in this disease45. In this study, we show
that Vps34 inhibition recapitulates some of the endolysosomal
defects seen in early stages of AD, namely enlargement of EEA1-
positive early endosomes46, stabilization of APPL1/Rab5-positive
endosomes and elevated APP-CTFβ47. Interestingly, Vps34
kinase inhibition led to a decrease in Aβ secretion in contrast to
the previously reported increase in secreted Aβ resulting from
partial knockdown of Vps34 in neurons15. This discrepancy may
reﬂect kinase-dependent effects vs. effects related to the destabi-
lization of the Vps34 complex, including Beclin 120, resulting
from loss of Vps34 protein scaffold. In fact, our results are sup-
ported by previous ﬁndings reporting that low speciﬁcity PI3K
inhibitors decrease Aβ secretion48. In addition, silencing ESCRT
component Hrs, which mediates PI3P-dependent sorting of
ubiquitinated cargoes into ILVs, drastically impairs Aβ secretion
in N2a cells49. However, the most striking APP-related phenotype
observed in cultured neurons as well as in vivo is the accumu-
lation of APP-CTFs, which is reminiscent of NPC50.
A key ﬁnding reported in this study is that reduction of PI3P
causes lipid dysregulation and physically damaged endolysosomal
membranes, as demonstrated by the enrichment of galectin-3 and
ﬂotillin-2 on p62-positive and ubiquitin-positive structures.
Because these structures were also detected in Vps34 KO primary
neurons (which present lower Beclin 1 levels20), we exclude that
secondary effects of pharmacological inhibition of Vps34, namely
upregulation of Beclin 1, underlie these phenotypes. While the
exact mechanism affecting endolysosomal integrity is unknown, it
likely results from lysosomal substrate accumulation. The aber-
rant accumulation of sphingolipids, such as dihydrosphingolipids
and Cer51,52, and sterols53 can potentially decrease lysosomal
enzymatic activity and destabilize endolysosomal membranes.
Alternatively, deﬁcient trafﬁcking or glycosylation of lysosomal
membrane proteins may decrease protection from hydrolases and
compromise membrane integrity54. This phenotype may be
striking after Vps34 inhibition since both autophagy and sorting
of p62 into lysosomes are reduced, thus preventing clearance of
these damaged organelles by lysophagy-like mechanisms28.
Relevant for neurodegenerative disorders, extracellular aggregates
of proteins such as α-synuclein55 and tau56,57 have been shown to
cause endolysosomal membrane rupture upon internalization,
perhaps facilitating their cell-to-cell transmission. One of the
potential implications of our study is that endolysosomal mem-
brane destabilization caused by PI3P deﬁciency may sensitize
neurons to aggregate-induced toxicity and pathology spreading.
Another important ﬁnding is the striking secretion of APP-
CTFs in exosomes derived from neurons undergoing endolyso-
somal stress. Exosomes are increasingly associated with the
transmission of aggregation-prone proteins58, but little is known
about the molecular mechanisms regulating their biogenesis,
cargo selection and secretion33. Recent studies have shown that
lysosomal alkalization by chloroquine promotes secretion of
exosomes harboring α-synuclein59 as well as the intracellular
domain of APP, but not APP-CTFs60. While the latter result
appears to be at odds with our BafA1 ﬁndings, it can be poten-
tially explained by the fact that BafA1 causes an irreversible
increase in lysosomal pH, unlike chloroquine. In fact, we found
that neither chloroquine nor ammonium chloride increase exo-
somal levels of APP-CTFs, despite causing increases in their
cellular levels (data not shown). Importantly, the fact that BafA1
partially phenocopies VPS34IN1 treatment suggests that blocking
Vps34 may affect the V-type ATPase, which will be tested in
future work. We also found that exosomal APP-CTF secretion
upon Vps34 inhibition largely occurs independently of the core
autophagy machinery, as Atg5-deﬁcient N2a cells accumulate
APP-CTFs intracellularly but do not secrete them to the same
extent as Vps34-inhibited cells. Similarly, γ-secretase inhibition
also fails to secrete large amounts of APP-CTFs on exosomes,
despite their cellular accumulation, providing additional evidence
that endolysosomal dysfunction, rather than intracellular APP-
CTF accumulation per se, is the mechanism driving exosomal
secretion of APP-CTFs. This process may minimize intracellular
processing of these APP metabolites by γ-secretase, thus reducing
Aβ generation and toxicity.
Our previous work showed that APP and APP-CTFs are sorted
into the ILVs of multivesicular endosomes through ESCRT
machinery in a pathway requiring PI3P and APP ubiquitina-
tion10,15. Of note, a subset of ILVs are known to be PI3P-positive
within these endosomes16. Because APP-CTFs are coenriched
with BMP on exosomes induced by Vps34 inhibition, PI3P
deﬁciency may shunt APP-CTFs into a distinct subpopulation of
ILVs which are BMP-positive and committed to the exosomal
pathway. This is consistent with the longstanding view that PI3P-
positive and BMP-positive ILVs are distinct within multivesicular
endosomes16. Importantly, it agrees with the view that PI3P/
ESCRT-independent pathways contribute to ILV biogenesis,
including the nSMase2 pathway41 as well as BMP itself16. Sup-
porting this view, APP-CTFs lacking ubiquitination sites in the
cytodomain61, thus preventing sorting via the ESCRT pathway15,
are released through exosomes as efﬁciently as wild-type APP-
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CTF upon Vps34 inhibition (data not shown). Interestingly, a
recent study showed that inhibition of autophagosome–lysosomal
fusion by tetraspanin-6 (TSPAN6) overexpression slowed the
degradation of APP-CTFs and increased secretion of EVs in a
process requiring syntenin62. This protein has been shown to
interact with ALIX, a modulator of BMP biological functions,
which include regulation of lysosomal lipases and storage of
endolysosomal cholesterol16. Whether TSPAN6-dependent exo-
somes share the same biological properties as those induced by
Vps34 inhibition is unclear. We also note that other studies have
not reported a BMP enrichment in exosomes63,64, likely reﬂecting
the fact that BMP-enriched exosomes are not secreted con-
stitutively, but rather released under endolysosomal stress.
Our study has also critical implications for biomarker dis-
covery. Indeed, increased BMP levels are a common feature of
several LSDs, including NPC26 and have been reported in the
brain of patients with AD27 and Lewy body disease (LBD)65, both
of which associated with endolysosomal dysfunction1. Our study
suggests that detection of BMP in bodily ﬂuids, such as blood,
cerebrospinal ﬂuid (CSF), and urine, may be more indicative of
exosomal secretion in response to LSD than a simple measure of
phospholipidosis66. APP-CTFs have also been reported in human
CSF67, suggesting that they can be helpful biomarkers in clinical
settings. In sum, APP-CTFs and BMP should be explored as
exosome-related biomarkers for a range of neurodegenerative
disorders, including AD, PD, LBD, FTD, ALS, and many LSDs.
Finally, an important question is whether exosomes released
upon endolysosomal dysfunction are endowed with speciﬁc cell
non-autonomous functions. Changes in EVs collected from
Pik3c3 cKO brain were subtler than those found in vitro, likely
reﬂecting the dynamic turnover and metabolism of exosomes
in vivo. For instance, they could convey “eat-me” signals directed
to microglia, ensuring the proper elimination of unhealthy neu-
rons through efferocytosis68 as well as of the neuronal waste they
carry. They could also present danger-associated molecular pat-
terns (“DAMPs”) affecting immune receptors68. Alternatively,
they could be vectors for the aggregation and/or spreading of
pathological proteins, including aberrant tau and Aβ42,69, or
constitute intracellular antigens triggering autoimmune
responses69.
In summary, our study reveals a speciﬁc homeostatic response
counteracting endolysosomal dysfunction via secretion of atypical
exosomes to eliminate lysosomal waste and deﬁne exosomal APP-
CTFs and BMP as candidate biomarkers diagnostic of endoly-
sosomal dysfunction associated with neurodegenerative disorders.
Methods
Reagents and antibodies. The following compounds were used: BafA1 (25 or 50
nM, 023–11641, Wako), cycloheximide (50 µg/ml, C4859, Sigma-Aldrich), EGF
(200 ng/ml, 01–101, EMD Millipore), GW4869 (10 µM, 13127, Cayman Chemi-
cals), SAR405 (1 µM, HY-12481, MedChem Express), VPS34IN1 (1 or 3 µM,
Dundee University), γ-secretase Inhibitor XXI, compound E (2 µM, 565790, EMD
Millipore). All compounds were dissolved in dimethyl sulfoxide (DMSO) and
control cells treated with 0.01% DMSO (Sigma-Aldrich). The following antibodies
were purchased from commercial sources: ALIX (pab0204, Rabbit (Rb), 1:2000 in
Western Blot (WB) of cell lysates and EVs, Covalab), ALIX (ABC40, Rb, 1:1000 in
WB of forebrain EVs, EMD Millipore), amyloid precursor protein C1/6.1 C-
terminal fragment (802801, Mouse (Ms), Biolegend, 1:500 in WB), APPL1
(ab59592, Rb, Abcam, 1:200 in IF and 1:1000 in WB), Atg12-Atg5 (2011, Rb, Cell
Signaling, 1:1000 in WB), Beclin 1 (3738, Rb, Cell Signaling, 1:1000 in WB), β-
Amyloid M3.2 (805701, Ms, Biolegend, 1:500 in WB), BIII-Tubulin (801201, Ms,
Biolegend, 1:1000 in immunoﬂuorescence (IF)), Calnexin (ab31290, Ms, Abcam,
1:200 in WB), EEA1 (sc-6415, Goat, Santa Cruz, 1:300 in IF), EEA1 (C45B10, Rb,
Cell Signaling, 1:1000 in WB), EGFR (06-847, Rabbit (Rb), EMD Millipore, 1:1000
in WB), Flotillin-1 (610820, Ms, BD Biosciences, 1:1000 in WB), Flotillin-2
(610383, Ms, BD Biosciences, 1:50 for IF and 1:1000 in WB), GAPDH (MCA-1D4,
Ms, Encor Biotech, 1:4000 in WB), Galectin-3 (sc-23938, Rat, Santa Cruz, 1:50 in
IF), GM130 (610823, Ms, BD Biosciences, 1:500 in WB), LAMP-1 (1D4B, Rat,
Developmental Studies Hybridoma Bank, 1:400 in IF), LAMP-1 (ab24170, Rb,
Abcam, 1:400 in IF and 1:500 in WB), LC3 (M152-3, Ms, MBL, 1:300 in IF), LC3
(NB100-2220, Rb, Novus Biomedical, 1:1000 in WB), MAP2 (ab5392, Chicken,
Abcam, 1:2000 in IF), p62 (03-GP62-C, Guinea Pig, American Research Produc-
tions, 1:1000 for IF and WB), Rab5 (108011, Ms, Synaptic Systems, 1:100 in IF and
1:500 in WB), Rab7 (9367, Rb, Cell Signaling, 1:1000 in WB), Ubiquitin (sc-8017,
Ms, Santa Cruz, 1:1000 in WB, 1:100 in IF), Tubulin (T6074, Ms, Sigma-Aldrich,
1:5000 in WB), Vps15 (H00030849-M02, Ms, Abnova, 1:1000 in WB), Vps34
(4263, Rb, Cell Signaling, 1:1000 in WB). Antibodies raised against ATG14L (Rb,
1:500 in WB) were a generous gift from Dr. Zhenyu Yue (Icahn School of Medicine
at Mount Sinai), anti-Cathepsin D (Rb, 1:10.000 in WB, 1:200 in IF) were a
generous gift from Dr. Ralph Nixon (Nathan Kline Institute) and anti-BMP/LBPA
(Ms, 1:50 in IF) were a generous gift from Dr. Jean Gruenberg (University of
Geneva).
Cell culture. Murine neuroblastoma N2a cells were maintained at 37 °C in a
humidiﬁed 5% CO2 atmosphere in DMEM with GlutaMAX supplemented with
10% fetal bovine serum and penicillin (100 U/ml), streptomycin (100 µg/ml)
(Thermoﬁsher). Cells were negative for mycoplasma contamination. CRISPR-Cas9
gene-edited ATG5 KO and isogenic N2a cells were a kind gift from Dr. Hermann
Schaetzl (University of Calgary). 24 h before drug treatment, cells were plated at
50% conﬂuence. Primary cortical neurons were generated from newborn wild-type
C57BL/6 or Pik3c3ﬂox/ﬂox mice. Brieﬂy, cortices were dissected and chemically
digested in 0.25% trypsin for 20 min at 37 °C. Cells were dissociated with a Pasteur
pipette, plated on poly-ornithine-coated dishes or glass coverslips at a density of
50,000–100,000 cells/cm2 and allowed to mature in Neurobasal-A supplemented
with 2 mM Glutamax and 2% B27 (Thermoﬁsher). Vps34 KO neurons were cul-
tured from Pik3c3ﬂox/ﬂox mice and infected with lentivirus carrying catalytically
active Cre recombinase or catalytically dead Cre (ΔCre)20 after 7 days in vitro and
grown up to 15 days. Lentiviruses were generated by transfecting HEK-293T with
lentiviral vectors and pPACK-H1 packaging mix (System Biosciences), using
lipofectamine LTX (Thermoﬁsher). HEK-293T media was collected 72 h post
transfection, passed through a 45 nm syringe ﬁlter, and applied to neuronal media.
Drug treatments were performed after 15–18 days in vitro in fresh medium con-
taining Neurobasal-A supplemented with 2% B27. Neuronal cell viability was
determined following manufacturer’s protocol using CCK8 kit (Dojindo) in cortical
neurons grown in 96-well plates, seeded at a density of 30,000 cells/well and grown
for 15 days in vitro.
Animals. Animals were used in full compliance with National Institute of Health/
Columbia University Institutional Animal Care and Use Committee guidelines.
The animal protocol was approved by the Committee on the Ethics of Animal
Experiments of Columbia University. Pik3c3ﬂox/ﬂox mice were a kind gift of Dr. Fan
Wang (Duke University School of Medicine) and have been previously descri-
bed12,13. Mice were crossed with transgenic mice expressing Cre recombinase
under the promoter of CaMKII to conditionally knockout Pik3c3 in excitatory
forebrain neurons. At 2 and 3 months of age, mice were killed by cervical dis-
location, brains immediately macro-dissected, frozen in liquid nitrogen, and stored
at −80 °C. In all experiments, littermate Pik3c3ﬂox/ﬂox; CaMKII-Cre (Pik3c3 cKO)
of both sexes were compared to Pik3c3ﬂox/ﬂox (CTRL).
Immunoﬂuorescence and confocal microscopy. Cultured cortical neurons were
ﬁxed in 2% paraformaldehyde (PFA, Alfa Aesar), 2% sucrose (Sigma-Aldrich) in
culture media for 15 min and permeabilized with 0.05% saponin in phosphate-
buffered saline (PBS, Boston Bioproducts) supplemented with 1% bovine serum
albumin (BSA, Sigma-Aldrich). Primary and Alexa Fluor conjugated secondary
antibodies (Thermoﬁsher, Jackson Immunoresearch) were sequentially incubated
for 1 h in the same buffer. Coverslips were mounted in ProLong Gold antifade
mountant (Thermoﬁsher). For immunohistochemistry, mice were transcardially
perfused with PBS. Brains were dissected and ﬁxed overnight in 4% PFA in PBS at
4 °C, followed by incubation in 30% sucrose (Sigma-Aldrich) for 48 h in PBS.
Brains were sectioned in coronal planes with a cryostat (Leica Biosystems).
Immunostaining was performed by blocking free-ﬂoating brain sections in 5%
Donkey Serum (Thermoﬁsher), 1% BSA and 0.2% Triton X-100 (Fisher Scientiﬁc)
in PBS for 1 h. Primary antibodies were incubated overnight at 4 °C and secondary
antibodies for 2 h at room temperature, both in blocking solution. Slices were
mounted in ProLong Gold antifade mountant (Thermoﬁsher). Confocal stacks and
super-resolution images were acquired using a Zeiss LSM 800 confocal microscope
equipped with Airyscan module (Zeiss). Fluorescence was collected with ×40 and
×63 plan apochromat immersion oil objectives. Extraction of single z-frame and
maximum intensity projections were performed with ImageJ software. Colocali-
zation was calculated with JACoP plugin of ImageJ and is expressed as Manders’
coefﬁcient. Object number, size and intensity were detected and quantiﬁed with the
ICY software. Each experiment was independently repeated at least three times,
unless indicated otherwise.
Conventional electron microscopy. Cultured cortical neurons were ﬁxed with
2.5% glutaraldehyde in 0.1 M cacodylate buffer (Electron Microscopy Sciences) for
24 h and processed as described previously15. Ultrathin sections were prepared
with an EM UC6 ultracryomicrotome (Leica). Exosomes puriﬁed from mice brain
(see below) were suspended in PBS and ﬁxed with a mixture of 2% PFA/0.065%
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glutaraldehyde in 0.2 M PBS at 4 °C. The suspension was loaded onto
formvar–carbon-coated EM grids (Electron Microscopy Sciences) and ﬁxed a
second time. Samples were contrasted and embedded in a mixture of uranyl acetate
and methylcellulose (Electron Microscopy Sciences). Images were acquired using a
Philips CM-12 electron microscope (FEI) and digital acquisitions made with a
Gatan (4 k × 2.7 k) digital camera (Gatan).
Protein biochemistry and immunoblotting. Cells were washed in PBS and
scraped in Radioimmunoprecipitation assay buffer (RIPA) (Pierce) supplemented
with protease and phosphatase inhibitor cocktail (Roche). Homogenates were
centrifuged for 10 min at 16,000 × g at 4 °C. Subcellular fractionation of particulate
and soluble fractions was performed as previously described70. Supernatants were
processed for protein dosage (BCA, Pierce) and samples diluted to equal con-
centration. SDS–PAGE was carried out per manufacturer’s protocol (Thermo-
ﬁsher). Samples (20–40 μg protein) were prepared with NuPage LDS sample buffer
and NuPage reducing reagent and loaded in NuPAGE 4–12% Bis–Tris gels;
separation was carried out using MES running buffer (Thermoﬁsher). Wet transfer
was performed on 0.22 µm nitrocellulose membranes (Amersham) at 80 V for
1h45 min at 4 °C using 0.05% SDS tris-glycine buffer (Boston BioProducts).
Membranes were blocked with 5% BSA for 45 min at room temperature. Primary
antibodies were diluted in blocking buffer and incubated overnight at 4 °C; HRP-
conjugated secondary antibodies were incubated for 90 min at room temperature.
Membrane development was performed with Immobilon Western Chemilumi-
nescent HRP Substrate (EMD Millipore) and the chemiluminescent signal was
imaged with ImageQuant LAS4000 mini (GE Healthcare). Quantiﬁcation was
performed with ImageJ. Analysis of APP-CTFs was done using NuPage 10–20%
Tricine gels (Thermoﬁsher). For analysis of mouse brain tissue, samples were
homogenized in 10 volumes of RIPA supplemented with protease and phosphatase
inhibitor cocktail (Roche). Homogenates were centrifuged at 16,000 × g for 15 min
and supernatants processed as described above. Uncropped blots are shown in
Supplementary Fig. 9.
Aβ measurements. Cortical neurons were grown 15 to 18 days in vitro. Neurons
were placed in fresh culture medium containing Neurobasal-A and 2% B27 and
treated for 24 h. Conditioned media was collected, treated with AEBSF protease
inhibitor (1 mM, Thermoﬁsher), centrifuged at 2000 × g for 5 min and stored at
–80 °C. Levels of Aβ40 and Aβ42 were measured using V-PLEX Aβ Peptide Panel 1
(4G8) kit (MesoScaleDiscovery, MSD) following the manufacturer’s protocol.
Mouse hippocampi were homogenized in 10 volumes of tissue homogenization
buffer (250 mM sucrose, 20 mM Tris base, 1 mM EDTA, 1 mM EGTA) and diluted
1:2 in 0.4% diethanolamine, 100 mM NaCl to extract soluble β-amyloid. Samples
were ultracentrifuged for 60 min, at 4 °C and 100,000 × g using a TLA55 rotor
(Beckman Coulter) and equilibrated with Tris-HCl (0.05 M). Murine Aβ40 and
Aβ42 were measured using Aβ40 and Aβ42 Mouse ELISA Kits (Thermoﬁsher)
following the manufacturer’s protocol. In both cases, samples were measured in
duplicates and values were normalized to protein concentration of cell or brain
lysates, respectively.
Exosome isolation. Primary cortical neurons were grown in 100 mm dishes or 6-
well plates at a density of 100,000 cells/cm2. Conditioned media was collected 24 to
36 h after treatment and exosomes isolated by differential centrifugation as pre-
viously described34,39, with minor modiﬁcations. Brieﬂy, samples were cleared of
cellular debris at 2000 × g for 20 min, ﬁltered through a 0.2 µm PES ﬁlter
(Worldwide Life Sciences) and ultracentrifuged for 90 min at 4 °C and 100,000 × g
using a Sw41 or TLA55 rotor (Beckman Coulter). Exosome pellets were washed in
PBS and ultracentrifuged for 90 min at 4 °C and 100,000 × g. Pellets were resus-
pended in RIPA buffer for Western blotting or in PBS for lipid analysis (see below).
Equal volumes of exosome resuspension were loaded on SDS–Page. For analysis of
N2a cell-derived exosomes, FBS was exosome-depleted by ultracentrifugation for
18 h, at 4 °C and 100,000 × g. Cells were grown in 10% FBS and media was pro-
cessed as described above. Puriﬁcation of exosomes was conﬁrmed by comparison
of exosomal and non-exosomal markers levels in lysates and EVs. Brain exosomes
were isolated as previously described42,44 with slight modiﬁcations. Brieﬂy, cortices
were minced and digested in hibernate A and papain for 20 min at 37 °C (Ther-
moFisher). Digestion was halted with the addition of excess hibernate A containing
protease and phosphatase inhibitors (Roche). The tissue was homogenized gently
with a serological pipette and cells were removed by centrifugation for 10 min at 4 °
C and 300 × g. The supernatant was passed through a 40 µm strainer (BD
Bioscience) followed by a 0.2 µm PES ﬁlter and subjected to serial centrifugations
for 10 min at 2000 × g and 30 min at 10,000 × g, at 4 °C, to remove cellular debris.
The resulting supernatant was centrifuged for 70 min at 4 °C and 100,000 × g,
washed with PBS and centrifuged again. Pellets were suspended in 3 mL of 40%
Optiprep (Sigma-Aldrich), overlaid with 3 mL of 20, 10, and 5% Optiprep solutions
and centrifuged for 18 h at 4 °C and 200,000 × g. One-ml fractions were collected,
diluted in PBS, and centrifuged again for 70 min at 4 °C and 100,000 × g. Pellets
were resuspended in RIPA for immunoblotting or PBS for EM and lipid analysis.
Fraction density was calculated by diluting a sample in three volumes of 0.25 M
sucrose and measuring optical density at 340 nm (Axis-Shield Density Gradient
Media). Validation of exosome puriﬁcation was performed in wild-type C57BL/6
mice by buoyancy, EM and enrichment of exosome markers ALIX and Flotillin-1.
Fractions containing exosomes were pooled together for downstream analyses.
Lipid analysis. Lipid extracts were prepared using a modiﬁed Bligh/Dyer extrac-
tion as previously described15. Brieﬂy, cells or mice hippocampi were resuspended
and homogenized in a solution of methanol:chloroform (2:1) and lipids extracted
using chloroform:KCl (3:2, 1 M). Extracted lipids were dried under vacuum and
stored at −80 °C. Extracts were spiked with appropriate internal standards and
analyzed by LC–MS. For analysis of anionic phospholipids and phosphoinositide,
extracted lipids were deacylated, and analyzed by anion-exchange high-perfor-
mance liquid chromatography with suppressed conductivity15. Lipid levels are
expressed as average Mol% of the total sum of moles of lipids detected. The
nomenclature abbreviations are: FC, free cholesterol; CE, cholesterol ester; MG,
monoacylglycerol; DG, diacylglycerol; TG, triacylglycerol; Cer, ceramide; dhCer;
dihydroceramide; SM, sphingomyelin; dhSM, dihydrosphingomyelin, MhCer,
monohexosylceramide; Sulf, sulfatide; LacCer, lactosylceramide; GM3, mono-
sialodihexosylganglioside; PA, phosphatidic acid; PC. Phosphatidylcholine; PCe,
ether phosphatidylcholine, PE, phosphatidylethanolamine, PEp, plasmalogen
phosphatidylethanolamine, PS, phosphatidylserine; PI, phosphatidylinositol; PG,
phosphatidylglycerol; BMP, bis(monoacyl)glycerol; LPC, lysophosphatidylcholine,
LPCe, ether lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; LPEp,
plasmalogen lysophosphatidylethanolamine; LPI, lysophosphatidylinositol.
Statistics. Statistical analysis was performed using Prism software (Graphpad). All
the data are given as mean ± s.e.m. for a given N of biological replicates. Results
were pooled from independent experiments as indicated. No statistical method was
used to determine sample size. Mice were randomized per litter with age-matched
controls and results pooled from at least two distinct litters. No blinding was done
for biochemical analyses. For comparison of two experimental conditions, two-
tailed Student’s t test was performed. One-way ANOVA followed by Holm–Sidak’s
multiple comparisons test was performed for analysis of additional experimental
groups. Analysis of time-course experiments was performed with two-way
ANOVA repeated measures followed by Holm–Sidak’s multiple comparisons test.
Exact p values are reported in Supplementary Table 1.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the paper and its supplementary information ﬁles. Data
are available from the corresponding author on request.
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